Current Edition:

Table of Contents

Editor's Note
Neil Love, MD

Adjuvant trastuzumab and cardiac function
 

Trastuzumab for patients with metastatic breast cancer
 

Algorithm for assessing HER2 status
 

ATAC trial results
  Follow-up to the NSABP P-1 trial
  Adjuvant ovarian ablation/tamoxifen
  Anti-vascular endothelial growth factor (VEGF) monoclonal antibody
  Select publications regarding adjuvant trastuzumab and cardiac function
 
Anthony Howell, BSc, MBBS, MSc, FRCP
Combination arm of the ATAC trial
  Defining ER positivity
  Implications of the ATAC trial in chemoprevention
  Impact of anastrozole on bone: Potential role of bisphosphonates
  Fulvestrant: An estrogen receptor downregulator
  Select publications regarding the use of bisphosphonates in breast cancer; fulvestrant
   
I Craig Henderson, MD
Implications of the ATAC trial for clinical practice
  Management of postmenopausal patients with ER-positive breast cancers
  The diminishing effect of chemotherapy in older women
  Postmenopausal ovarian function
  Effect of chemotherapy in ER-positive patients
  Select publications regarding adjuvant use of aromatase inhibitors; endocrine effects of systemic therapy
   
Eleftherios P Mamounas, MD
NSABP B-27: Response rates to neoadjuvant AC-> docetaxel
  Neoadjuvant capecitabine/docetaxel trial
  NSABP B-30: Sequential versus combination chemotherapy in the adjuvant setting
  Adjuvant chemotherapy for elderly women
  Adjuvant trastuzumab in HER2-positive, node-positive patients
  NSABP B-34: Adjuvant clodronate
  Proposed NSABP trial of anastrozole in women with DCIS
  Select publications regarding neoadjuvant chemotherapy; local recurrence
   

 

BCU SURGEONS | 2002

 


 
Home · Contact us
Terms of use and general disclaimer
© NL Communications, Inc. 2003. All rights reserved.